BlackRock’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-354
| Closed | -$1.33K | – | 5510 |
|
|
2024
Q3 | $1.33K | Sell |
354
-82
| -19% | -$471 | ﹤0.01% | 5126 |
|
|
2024
Q2 | $4.16K | Sell |
436
-1
| -0.2% | -$34 | ﹤0.01% | 5138 |
|
|
2024
Q1 | $33.1K | Hold |
437
| – | – | ﹤0.01% | 4950 |
|
|
2023
Q4 | $77.8K | Sell |
437
-4
| -0.9% | -$1.97K | ﹤0.01% | 4873 |
|
|
2023
Q3 | $312K | Buy |
441
+3
| +0.7% | +$12.9K | ﹤0.01% | 4556 |
|
|
2023
Q2 | $2.01M | Buy |
438
+5
| +1% | +$17.3K | ﹤0.01% | 4050 |
|
|
2023
Q1 | $1.15M | Sell |
433
-32
| -7% | -$93.7K | ﹤0.01% | 4290 |
|
|
2022
Q4 | $1.21M | Buy |
465
+2
| +0.4% | +$6.97K | ﹤0.01% | 4349 |
|
|
2022
Q3 | $1.83M | Hold |
463
| – | – | ﹤0.01% | 4236 |
|
|
2022
Q2 | $1.21M | Sell |
463
-1,176
| -72% | -$3.06M | ﹤0.01% | 4463 |
|
|
2022
Q1 | $5.27M | Sell |
1,639
-70
| -4% | -$301K | ﹤0.01% | 3925 |
|
|
2021
Q4 | $10.7M | Buy |
1,709
+47
| +3% | +$361K | ﹤0.01% | 3636 |
|
|
2021
Q3 | $15.4M | Buy |
1,662
+271
| +19% | +$2.33M | ﹤0.01% | 3450 |
|
|
2021
Q2 | $14.1M | Buy |
1,391
+1,080
| +347% | +$17.7M | ﹤0.01% | 3503 |
|
|
2021
Q1 | $5.95M | Buy |
311
+167
| +116% | +$1.95M | ﹤0.01% | 3859 |
|
|
2020
Q4 | $876K | Hold |
144
| – | – | ﹤0.01% | 4242 |
|
|
2020
Q3 | $520K | Hold |
144
| – | – | ﹤0.01% | 4257 |
|
|
2020
Q2 | $560K | Buy |
144
+33
| +30% | +$110K | ﹤0.01% | 4183 |
|
|
2020
Q1 | $210K | Buy |
111
+6
| +6% | +$22.3K | ﹤0.01% | 4222 |
|
|
2019
Q4 | $541K | Buy |
105
+23
| +28% | +$88.2K | ﹤0.01% | 4142 |
|
|
2019
Q3 | $288K | Buy |
82
+1
| +1% | +$6.03K | ﹤0.01% | 4264 |
|
|
2019
Q2 | $682K | Buy |
81
+11
| +16% | +$116K | ﹤0.01% | 4119 |
|
|
2019
Q1 | $908K | Buy |
70
+69
| +6,900% | +$1.12M | ﹤0.01% | 3940 |
|
|
2018
Q4 | $16K | Hold |
1
| – | – | ﹤0.01% | 4612 |
|
|
2018
Q3 | $27K | Hold |
1
| – | – | ﹤0.01% | 4625 |
|
|
2018
Q2 | $33K | Hold |
1
| – | – | ﹤0.01% | 4612 |
|
|
2018
Q1 | $36K | Hold |
1
| – | – | ﹤0.01% | 4485 |
|
|
2017
Q4 | $161K | Hold |
1
| – | – | ﹤0.01% | 4257 |
|
|
2017
Q3 | $150K | Buy |
+1
| New | +$164K | ﹤0.01% | 4293 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 4764 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4634 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3829 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3666 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 3695 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 3472 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 3277 |
|
Other funds holding SEEL
BlackRock's SEEL Position: Q4 2024 in Review
BlackRock sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 354 shares — an estimated $1.33K sold.
BlackRock first reported a position in SEEL in Q3 2017 and held it in 29 quarters. The position peaked at $15.4M in Q3 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.
- BlackRock reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- BlackRock sold 354 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $1.33K.
- BlackRock first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2017 and held it in 29 quarters.
- BlackRock's Seelos Therapeutics, Inc. Common Stock position peaked at $15.4M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.
Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.